(Q39752237)

English

INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 September 2017

INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support (English)

1 reference

Europe PubMed Central

14 September 2017

author name string

Jun Li

1

1 reference

Europe PubMed Central

14 September 2017

Margaret Favata

2

1 reference

Europe PubMed Central

14 September 2017

Jennifer A Kelley

3

1 reference

Europe PubMed Central

14 September 2017

Eian Caulder

4

1 reference

Europe PubMed Central

14 September 2017

Beth Thomas

5

1 reference

Europe PubMed Central

14 September 2017

Xiaoming Wen

6

1 reference

Europe PubMed Central

14 September 2017

Richard B Sparks

7

1 reference

Europe PubMed Central

14 September 2017

Ari Arvanitis

8

1 reference

Europe PubMed Central

14 September 2017

James D Rogers

9

1 reference

Europe PubMed Central

14 September 2017

Andrew P Combs

10

1 reference

Europe PubMed Central

14 September 2017

Kris Vaddi

11

1 reference

Europe PubMed Central

14 September 2017

Kimberly A Solomon

12

1 reference

Europe PubMed Central

14 September 2017

Peggy A Scherle

13

1 reference

Europe PubMed Central

14 September 2017

Robert Newton

14

1 reference

Europe PubMed Central

14 September 2017

Jordan S Fridman

15

1 reference

Europe PubMed Central

14 September 2017

publication date

1 January 2010

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

12

1 reference

Europe PubMed Central

14 September 2017

1

1 reference

Europe PubMed Central

14 September 2017

28-38

1 reference

Europe PubMed Central

14 September 2017

Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Bone marrow microenvironment and the identification of new targets for myeloma therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Hematopoietic cytokine receptor signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Jak3 and the pathogenesis of severe combined immunodeficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Advances in biology of multiple myeloma: clinical applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Interleukin-6 in human multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

22 September 2017

Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

25 September 2017

IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

25 September 2017

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

25 September 2017

Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

25 September 2017

Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

25 September 2017

The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

17 June 2018

Interleukin-6 prevents dexamethasone-induced myeloma cell death.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

17 June 2018

Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

17 June 2018

Interleukin-6 dependence of advanced malignant plasma cell dyscrasias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

17 June 2018

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

20 August 2018

SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

20 August 2018

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

20 August 2018

A novel method for measurement of submembrane ATP concentration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805881

20 August 2018

Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11

1 reference

https://pubmed.ncbi.nlm.nih.gov/20072651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 inhibits apoptosis of malignant plasma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20072651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B

1 reference

https://pubmed.ncbi.nlm.nih.gov/20072651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20072651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/20072651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Production of cytokines by bone marrow cells obtained from patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20072651

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1593/NEO.91192

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39752237&oldid=2089912911"